Browsing Tag
Jonathan Graf
1 post
AnaptysBio shares soar 37% after rheumatoid arthritis candidate rosnilimab delivers promising Phase 2b trial results
AnaptysBio, Inc. experienced a significant boost in its market performance as shares surged 37% in premarket trading following…